DOCSLIB.ORG

Cervical Dysplasia and Invasive Cervical Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cervical Dysplasia and Invasive Cervical Cancer Cervical Dysplasia and Faculty Invasive Cervical Cancer Satellite Conference and Live Webcast Friday, October 10, 2008 Michael A. Finan, M.D., F.A.C.S. 1:00 - 3:00 p.m. Chief, Gynecologic Oncology Produced by the Alabama Department of Public Health Video Communications and Distance Learning Division Objectives Objectives • Overview of cervical cancer • Understand staging of cervical cancer • Understand Role of HPV • Describe treatment of various stages of • Apply algorithms from www.asccp.org cervical cancer • Apply methods of diagnosis of cervical • Understand roles of surgery, radiation cancer therapy and chemotherapy for the management of cervical cancer 1 Cervical Dysplasia Epidemiology • Schauenstein (1908) first proposed that SCC • Abnormal Pap = 3.5 million per year (7%) of cervix evolves by a progression of a • CIS = 50,000 per year preinvasive lesion (carcinoma in situ) • CXCA = 13,000 per year – 4,500 deaths per year • Overall incidence: 8.7/100,000 women Papanicolaou described CIS and less • • Second most common female cancer anaplastic lesions called dysplasia worldwide • Among top 5 causes cancer death in developing countries (20-30% of female • WHO defines dysplasia as “lesion in which cancers) part of the epithelium is replaced by cells – Pap decreased cancer by 50% in showing varying degrees of atypia.” U.S.! Risk Factors • Age first intercourse • Low • Multiple partners (>2) socioeconomic status • STD > 3 years pap • HPV • High risk partner • High risk HPV • Other • Immunosuppression • • Smoking – Contraceptive hormones – Radiation HPV Human Papilloma Virus • Non-enveloped DNA encased in capsid > 80 subtypes (31 anogenital) • E2 transcriptional regulation of HPV • HPV stronger association with cancer genes E2 E5 Integration Epidemic past 20 yrs disrupts E2 • E4 leading to L2 • HPV DNA found > 95% of SCC E1 increased E6/E7 Late genes encode capsid HPV-16 transcription • Not only factor proteins E7 L1 E7 binds pRb • 43% college women HPV+ (but <5% E6 LCR CIN) E6 binds p53 2 HPV Types Cervical Dysplasia Schematic High Risk HPV Testing Low Risk Intermediate High Outer 1/3 Risk Risk 31, 33, 35, Middle 1/3 6, 11, 26, 39, 51, 52, 16, 18, 42, 44, 54, Inner 1/3 55, 58, 59, 45, 56 70, 73 66, 68 • Low Risk: never found alone in invasive cancer • HPV-16: more common in squamous lesions • HPV-18: more common in endocervical lesions “In The Zone” Understanding The Cervical • Cervix mullerian duct origin Transformation Zone • Lined by columnar epithelium E2 • 18-20 wks. gestation colonized by squamous epithelium E2 • Squamocolumnar Junction = Transformation Zone E2 • Zone changes position depending on hormonal influence From: Practical Gynecologic Oncology 3rd Ed. Berek & Hacker Screening Is Good Bethesda 2001 • Cervical cancer #1 in incidence & • Specimen type mortality in women prior to 20th century • Specimen Adequacy • Screening for premalignant lesions – Satisfactory knocked it down to #2 worldwide – Unsatisfactory due to… (yipee) • General Categorization • Dichotomy b/t developing & developed – Negative, Epithelial cell abnormality, countries other • “Preventable disease” 3 Bethesda 2001 Bethesda 2001 • Interpretation and Result • Squamous Cell – Negative for Intraepithelial Lesion or – Atypical Squamous Cells Malignancy • ASC-US • Organisms • ASC-H –Trich, Candida, BV, HSV, etc – LSIL (HPV, mild dysplasia) • Other – HSIL –Reactive inflammation, IUD, • Moderate dysplasia radiation, Atrophy • Severe dysplasia Bethesda 2001 Bethesda 2001 Abnormalities • Squamous Cell • Squamous Cell – Squamous Cell Carcinoma – Atypical Squamous Cells ASC-US • Glandular Cell • • ASC-H (can’t r/o high grade lesion) – Atypical Endocervical, Endometrial, – LSIL (HPV, mild dysplasia) Glandular cells – HSIL AG-NOS • • Moderate dysplasia • AG-favor neoplasia • Severe dysplasia – Adenocarcinoma – Squamous Cell Carcinoma Bethesda 2001 Abnormalities Dysplasia Natural History • Glandular Cell Progress Progress Biopsy Regress Persist to – Atypical Endocervical, Endometrial, to CIN 3 Cancer Glandular cells CIN1 57% 32% 11% <1% • AG-NOS • AG-favor neoplasia CIN2 43% 35% 22% 5% – Adenocarcinoma CIN3 32% 56% N/A 12% Ostor AG. Int J Gyn Path. 1993 4 Infectious Or Neoplastic? Bottom Line Normal Infection Neoplasia Differentiate • No Neoplasia • Infection (HPV) • Neoplasia • No Infection • No Neoplasia • Infection normal from infectious Pap Normal Normal ASCUS ASCUS ASCUS LSIL and LSIL LSIL HSIL HSIL infectious from neoplastic Colposcopy The Colposcope • Adequacy? – visualize entire TZ and entire lesion (if any) • Visualize with Green filter- atypical vascularity • 3-5% acetic acid solution – Dries cells, neoplastic cells with higher nuclear:cytoplasmic ratio Colposcopy Colposcopy • Lugol’s Solution (1/4 strength)- Shiller’s Test • Endocervical Curettage (ECC) – Taken up by glycogen containing normal – Identify dysplasia within endocervical epithelium canal – Not taken up by atrophic or neoplastic – Controversial epithelium or columnar epithelium – Some studies show cytobrush sampling more sensitive although less specific 5 Colposcopic Findings Normal? Acetowhite Acetowhite • Acetowhite Changes – Increased N:C ratio – Abnormal intracellular keratins – Intracellular dehydration Before Acetic Acid After Acetic Acid Colposcopic Findings Punctation And Mosaicism • Abnormal vascularity Punctation Mosaicism – Punctation and Mosaicism • HPV capillary proliferative effect • Intraepithelial pressure created by expanding neoplastic tissue • Tumor angiogenesis factor – Atypical blood vessels • Margins Rolled, peeling edges or internal – • Epithelial proliferation squeezes demarcation between areas of differing appearance are abnormal capillaries up to surface Where’s the Dysplasia? Abnormal Vascularity Punctation Coarse Mosaicism & Punctation 6 Colposcopic Warning Colposcopic Warning Signs Of Invasion Signs Of Invasion • Friable epithelium with contact • Extremely abnormal punctation and bleeding mosaicism • Irregular surface contour • High grade lesions occupying 3 or 4 quadrants • Surface ulceration or erosion • High grade lesions extending into canal • Atypical blood vessels either >5mm or beyond colposcopic view Lugol’s Tischler Biopsy Instrument Is this Normal? Nabothian Cyst Cancer Lugol’s Iodine Application Interventional Techniques Biopsy Diagram • Excision – Cold Knife Cone – Loop Electrosurgical Excision Procedure (LEEP, LLETZ, LOOP) – Laser Cone • Ablation – Cyrotherapy – Laser vaporization therapy 7 Cold Knife Cone Cold Knife Cone • Lugol’s to delineate lesion • Tag 12 o’clock for orientation • Stay sutures at 3 and 9 o’clock for • +/- ECC or D&C traction & hemostasis • Cauterize base • Intracervical vasopressin for – Sturmdorf sutures not advisable hemostasis because of risk of burying residual • Sound endocervical canal to guide disease excision • Conical excision with #11 blade LEEP Cold Knife Cone Illustration • Visualize cervix with non-conductive speculum with suction attachment • Lugol’s to define lesion • Paracervical and intracervical block with Lidocaine • 35-55W or either cutting or blend LEEP LEEP Diagram • Excise area 7-10mm deep at center – Maximum depth of involved glands 5.2mm • Ball electrode cautery to base and periphery with coag current • +/- ECC • Monsel’s as needed for hemostasis 8 ASC-H Slide HPV Testing- ALTS Side Effects Of LEEP LSIL Algorithm Distribution • Bleeding (now & later) All Paps Pap normal ≥ ASCUS • Infection 92% 8% CIN2+ 15% • Damage to adjacent organs HSIL LSIL ASCUS 0.5% 2% 5% • Cervical incompetence High risk High risk High risk • Cervical stenosis HPV pos CIN2+ HPV pos HPV pos 25% 97%* 89% 53% HPV Triage reduces *Missing or false neg values Colpo of ASCUS by 50% ASC-US Summary ASC-US Algorithm • If using Thin Prep/HPV testing – ASC-US HPV test and colpo if (+) • If (-) then repeat HPV test only in 1 yr. (or repeat Pap) – >ASC-US Colpo • If not using ThinPrep/HPV – Colpo for ASC-US*2 – If ASC-H or greater Colpo See www.asccp.org Atypical Glandular Cells of Undetermined Significance AGUS Algorithm (AGUS) • Where are glandular cells? • Endometrium • Endocervix 9 AGUS Mgmt of AGUS HSIL AGUS Difficult to differentiate HSIL from AGUS on Pap Significance Of AGUS AGUS Summary High Any HSIL • Colpo with ECC for everyone Grade Pap (including Glandular squamous) Lesion • Endometrial Bx if >35 or history of AGUS 5-39% 1-8% Reactive irregular bleeding (suspicion of AGUS NOS 9-41% 0-15% endometrial hyperplasia or CA) AGUS favor 27-96% 10-93% neoplasia See www.asccp.org Special Circumstances- ASC-US Adolescent Postmenopausal • Vaginal atrophy causes cells to resemble HSIL or ASCUS – Predominance of smaller basal cells • If atrophy present, treat with vaginal Estrogen for 6 weeks and re-evaluate See www.asccp.org 10 ASC-H ASC-High Grade • ASC- Can’t rule out high grade All Paps lesion – 87% High-risk Pap normal ≥ ASCUS HPV positive 92% 8% – 30% CIN2 or CIN3 on CIN biopsy HSIL LSIL ASCUS 2+ 0.5% 2% 5% 15% • Immediate HPV HPV HPV CIN pos pos Colposcopy pos 2+ 97%* 89% 53% 25% See www.asccp.org LSIL HSIL- “See & Treat” • HSIL Severe Dysplasia (in multiparous All Paps • Almost all women) High Risk – Who doesn’t get LEEP? HPV positive Pap normal ≥ ASCUS – HPV 92% 8% – If negative or CIN1 on colpo- where’s testing CIN the HSIL coming from? useless HSIL LSIL ASCUS 2+ 0.5% 2% 5% 15% • LEEP for diagnosis (not if • 30% CIN2/3 nulliparous) • Immediate – If CIN2/3 on colpo then LEEP for HPV HPV HPV Colpo pos CIN2 treatment pos pos + 97%* • Management may differ in 89% 53% 25% See www.asccp.org See www.asccp.org pregnancy, adolescence
Load more

Recommended publications
  • Updates in Uterine and Vulvar Cancer
    Management of GYN Malignancies Junzo Chino MD Duke Cancer Center ASTRO Refresher 2015 Disclosures • None Learning Objectives • Review the diagnosis, workup, and management of: – Cervical Cancers – Uterine Cancers – Vulvar Cancers Cervical Cancer Cervical Cancer • 3rd most common malignancy in the World • 2nd most common malignancy in women • The Leading cause of cancer deaths in women for the developing world • In the US however… – 12th most common malignancy in women – Underserved populations disproportionately affected > 6 million lives saved by the Pap Test “Diagnosis of Uterine Cancer by the Vaginal Smear” Published Pap Test • Start screening within 3 years of onset of sexual activity, or at age 21 • Annual testing till age 30 • If no history of abnormal paps, risk factors, reduce screening to Q2-3 years. • Stop at 65-70 years • 5-7% of all pap tests are abnormal – Majority are ASCUS Pap-test Interpretation • ASCUS or LSIL –> reflex HPV -> If HPV + then Colposcopy, If – Repeat in 1 year • HSIL -> Colposcopy • Cannot diagnose cancer on Pap test alone CIN • CIN 1 – low grade dysplasia confined to the basal 1/3 of epithelium – HPV negative: repeat cytology at 12 months – HPV positive: Colposcopy • CIN 2-3 – 2/3 or greater of the epithelial thickness – Cold Knife Cone or LEEP • CIS – full thickness involvement. – Cold Knife Cone or LEEP Epidemiology • 12,900 women expected to be diagnosed in 2015 – 4,100 deaths due to disease • Median Age at diagnosis 48 years Cancer Statistics, ACS 2015 Risk Factors: Cervical Cancer • Early onset sexual activity • Multiple sexual partners • Hx of STDs • Multiple pregnancy • Immune suppression (s/p transplant, HIV) • Tobacco HPV • The human papilloma virus is a double stranded DNA virus • The most common oncogenic strains are 16, 18, 31, 33 and 45.
    [Show full text]
  • Treating Cervical Cancer If You've Been Diagnosed with Cervical Cancer, Your Cancer Care Team Will Talk with You About Treatment Options
    cancer.org | 1.800.227.2345 Treating Cervical Cancer If you've been diagnosed with cervical cancer, your cancer care team will talk with you about treatment options. In choosing your treatment plan, you and your cancer care team will also take into account your age, your overall health, and your personal preferences. How is cervical cancer treated? Common types of treatments for cervical cancer include: ● Surgery for Cervical Cancer ● Radiation Therapy for Cervical Cancer ● Chemotherapy for Cervical Cancer ● Targeted Therapy for Cervical Cancer ● Immunotherapy for Cervical Cancer Common treatment approaches Depending on the type and stage of your cancer, you may need more than one type of treatment. For the earliest stages of cervical cancer, either surgery or radiation combined with chemo may be used. For later stages, radiation combined with chemo is usually the main treatment. Chemo (by itself) is often used to treat advanced cervical cancer. ● Treatment Options for Cervical Cancer, by Stage Who treats cervical cancer? Doctors on your cancer treatment team may include: 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 ● A gynecologist: a doctor who treats diseases of the female reproductive system ● A gynecologic oncologist: a doctor who specializes in cancers of the female reproductive system who can perform surgery and prescribe chemotherapy and other medicines ● A radiation oncologist: a doctor who uses radiation to treat cancer ● A medical oncologist: a doctor who uses chemotherapy and other medicines to treat cancer Many other specialists may be involved in your care as well, including nurse practitioners, nurses, psychologists, social workers, rehabilitation specialists, and other health professionals.
    [Show full text]
  • WHO Guidelines for Treatment of Cervical Intraepithelial Neoplasia 2–3 and Adenocarcinoma in Situ
    WHO guidelines WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ Cryotherapy Large loop excision of the transformation zone Cold knife conization WHO guidelines WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization Catalogage à la source : Bibliothèque de l’OMS WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization. 1.Cervical Intraepithelial Neoplasia – diagnosis. 2.Cervical Intraepithelial Neoplasia – therapy. 3.Cervical Intraepithelial Neoplasia – surgery. 4.Adenocarcinoma – diagnosis. 5.Adenocarcinoma – therapy. 6.Cryotherapy – utilization. 7.Conization – methods. 8.Uterine Cervical Neoplasms – prevention and control. 9.Guideline. I.World Health Organization. ISBN 978 92 4 150677 9 (Classification NLM : WP 480) © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Cervical Cancer
    Cervical Cancer Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University Estimated gynecologic cancer cases United States 2010 Jemal, A. et al. CA Cancer J Clin 2010; 60:277-300 1 Estimated gynecologic cancer deaths United States 2010 Jemal, A. et al. CA Cancer J Clin 2010; 60:277-300 Decreasing Trends of Cervical Cancer Incidence in the U.S. • With the advent of the Pap smear, the incidence of cervical cancer has dramatically declined. • The curve has been stable for the past decade because we are not reaching the unscreened population. Reprinted by permission of the American Cancer Society, Inc. 2 Cancer incidence worldwide GLOBOCAN 2008 Cervical Cancer New cases Deaths United States 12,200 4,210 Developing nations 530,000 275,000 • 85% of cases occur in developing nations ¹Jemal, CA Cancer J Clin 2010 GLOBOCAN 2008 3 Cervical Cancer • Histology – Squamous cell carcinoma (80%) – Adenocarcinoma (15%) – Adenosquamous carcinoma (3 to 5%) – Neuroendocrine or small cell carcinoma (rare) Human Papillomavirus (HPV) • Etiologic agent of cervical cancer • HPV DNA sequences detected is more than 99% of invasive cervical carcinomas • High risk types: 16, 18, 45, and 56 • Intermediate types: 31, 33, 35, 39, 51, 52, 55, 58, 59, 66, 68 HPV 16 accounts for ~80% of cases HPV 18 accounts for 25% of cases Walboomers JM, Jacobs MV, Manos MM, et al. J Pathol 1999;189(1):12-9. 4 Viral persistence and Precancerous progression Normal lesion cervix Regression/ clearance Invasive cancer Risk factors • Early age of sexual activity • Cigggarette smoking • Infection by other microbial agents • Immunosuppression – Transplant medications – HIV infection • Oral contraceptive use • Dietary factors – Deficiencies in vitamin A and beta carotene 5 Multi-Stage Cervical Carcinogenesis Rosenthal AN, Ryan A, Al-Jehani RM, et al.
    [Show full text]
  • Colposcopy of the Uterine Cervix
    THE CERVIX: Colposcopy of the Uterine Cervix • I. Introduction • V. Invasive Cancer of the Cervix • II. Anatomy of the Uterine Cervix • VI. Colposcopy • III. Histology of the Normal Cervix • VII: Cervical Cancer Screening and Colposcopy During Pregnancy • IV. Premalignant Lesions of the Cervix The material that follows was developed by the 2002-04 ASCCP Section on the Cervix for use by physicians and healthcare providers. Special thanks to Section members: Edward J. Mayeaux, Jr, MD, Co-Chair Claudia Werner, MD, Co-Chair Raheela Ashfaq, MD Deborah Bartholomew, MD Lisa Flowers, MD Francisco Garcia, MD, MPH Luis Padilla, MD Diane Solomon, MD Dennis O'Connor, MD Please use this material freely. This material is an educational resource and as such does not define a standard of care, nor is intended to dictate an exclusive course of treatment or procedure to be followed. It presents methods and techniques of clinical practice that are acceptable and used by recognized authorities, for consideration by licensed physicians and healthcare providers to incorporate into their practice. Variations of practice, taking into account the needs of the individual patient, resources, and limitation unique to the institution or type of practice, may be appropriate. I. AN INTRODUCTION TO THE NORMAL CERVIX, NEOPLASIA, AND COLPOSCOPY The uterine cervix presents a unique opportunity to clinicians in that it is physically and visually accessible for evaluation. It demonstrates a well-described spectrum of histological and colposcopic findings from health to premalignancy to invasive cancer. Since nearly all cervical neoplasia occurs in the presence of human papillomavirus infection, the cervix provides the best-defined model of virus-mediated carcinogenesis in humans to date.
    [Show full text]
  • UNMH Obstetrics and Gynecology Clinical Privileges Name
    UNMH Obstetrics and Gynecology Clinical Privileges Name:____________________________ Effective Dates: From __________ To ___________ All new applicants must meet the following requirements as approved by the UNMH Board of Trustees, effective April 28, 2017: Initial Privileges (initial appointment) Renewal of Privileges (reappointment) Expansion of Privileges (modification) INSTRUCTIONS: Applicant: Check off the “requested” box for each privilege requested. Applicants have the burden of producing information deemed adequate by the Hospital for a proper evaluation of current competence, current clinical activity, and other qualifications and for resolving any doubts related to qualifications for requested privileges. Department Chair: Check the appropriate box for recommendation on the last page of this form. If recommended with conditions or not recommended, provide condition or explanation. OTHER REQUIREMENTS: 1. Note that privileges granted may only be exercised at UNM Hospitals and clinics that have the appropriate equipment, license, beds, staff, and other support required to provide the services defined in this document. Site-specific services may be defined in hospital or department policy. 2. This document defines qualifications to exercise clinical privileges. The applicant must also adhere to any additional organizational, regulatory, or accreditation requirements that the organization is obligated to meet. ---------------------------------------------------------------------------------------------------------------------------------------
    [Show full text]
  • Pretest Obstetrics and Gynecology
    Obstetrics and Gynecology PreTestTM Self-Assessment and Review Notice Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the prod- uct information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs. Obstetrics and Gynecology PreTestTM Self-Assessment and Review Twelfth Edition Karen M. Schneider, MD Associate Professor Department of Obstetrics, Gynecology, and Reproductive Sciences University of Texas Houston Medical School Houston, Texas Stephen K. Patrick, MD Residency Program Director Obstetrics and Gynecology The Methodist Health System Dallas Dallas, Texas New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto Copyright © 2009 by The McGraw-Hill Companies, Inc.
    [Show full text]
  • A Ten-Year Retrospective Study of Cervical Conization Followed by Hysterectomy for Various Grades of Cervical Intraepithelial Neoplasia
    A ten-year retrospective study of cervical conization followed by hysterectomy for various grades of cervical intraepithelial neoplasia CLAYTON T. SHAW, D 0 Omaha, Nebraska HEINZ 0. OSTERHOLZER, m D Philadelphia, Pennsylvania DAVID M. EVANS, m D Wiesbaden, West Germany They are: (1) visualization of the entire lesion; (2) A ten-year retrospective study of expertise in colposcopy; (3) exclusion of invasive seventy-seven patients from January carcinoma by punch biopsy; (4) adequate cytologic 1971 to December 1980, at the Tripler and colposcopic follow-up; and (5) endocervical Army Medical Center, who curettage. underwent cold knife conization for Conization as a modality, however, is considered cervical intraepithelial neoplasia a definitive therapy for the removal of dysplastic (CIN) followed by hysterectomy, was tissue and is required if the colposcopic examina- performed to determine the tion is inadequate or the endocervical curettage is predictive value of cone clearance positive for CIN. Kolstad stated that conization is regarding residual CIN. Forty-four of the method of choice for carcinoma in situ. He the seventy-seven patients had found a 97 percent cure rate with 1 percent pro- clear cone margins but seven of these gressing to invasive carcinoma and 2 percent to re- forty-four had residual CIN at the current carcinoma in situ. Caglar 9 also studied the time of hysterectomy. This accuracy of the cervical cone. He performed coniza- represented a 15.9 percent tion in thirty-three patients and immediately fol- recurrence rate. Thirty-three patients lowed that procedure with a vaginal hysterectomy. had margins involved at the time of He found that in three patients (9 percent) of the conization, but only fourteen of these uteri specimens had the same diagnosis as the con- (42.4 percent) demonstrated residual ization.
    [Show full text]
  • Cervical Health Policies Program Description the Breast, Cervical and Colon Health Program (BCCHP) Screens Qualifying Clients for Cervical Cancer
    DOH 342-035 July 2018 Cervical Health Policies Program Description The Breast, Cervical and Colon Health Program (BCCHP) screens qualifying clients for cervical cancer. The program is funded through a grant from the Centers for Disease Control and Prevention (CDC). It is administered by the Washington State Department of Health which contracts with Prime Contractors throughout the state to implement the program regionally. The Prime Contractors subcontract with health care providers and organizations to provide direct services to individuals in their communities. BCCHP eligibility and screening policies reflect CDC guidelines. Eligibility & Coverage Gender Definitions for terms used in BCCHP policies • Cisgender - a person whose gender identification and birth sex are the same. • Transgender man - a person who identifies as male with a female-assigned birth sex. • Transgender woman - a person who identifies as female with a male-assigned birth sex. • Genderqueer - A person whose gender identity differs from the gender assigned at birth, but may less clearly defined than a transgender person. • Gender Non-binary - a person who neither identifies as a male nor female with either a female assigned birth sex or a male-assigned birth sex. • Agender – A person who does not identify with any gender. Eligible – Cisgender women and transgender men who meet the following criteria: Must meet all of the following: • Age 40-64 (through the end of the month of client’s 65th birthday). • Age 65+ if the client is not eligible for Medicare or ineligible for Medicare Part B at the time of enrollment. • Age 21-39 if the client is not covered by Family Planning or Title X Clinic funding.
    [Show full text]
  • Colposcopy, Treatment of Cervical Intraepithelial Neoplasia, and Endometrial Assessment BARBARA S
    Gynecologic Procedures: Colposcopy, Treatment of Cervical Intraepithelial Neoplasia, and Endometrial Assessment BARBARA S. APGAR, MD; AMANDA J. KAUFMAN, MD; CATHERINE BETTCHER, MD; and EBONY PARKER-FEATHERSTONE, MD, University of Michigan Medical Center, Ann Arbor, Michigan Women who have abnormal Papanicolaou test results may undergo colposcopy to determine the biopsy site for his- tologic evaluation. Traditional grading systems do not accurately assess lesion severity because colposcopic impres- sion alone is unreliable for diagnosis. The likelihood of finding cervical intraepithelial neoplasia grade 2 or higher increases when two or more cervical biopsies are performed. Excisional and ablative methods have similar treatment outcomes for the eradication of cervical intraepithelial neoplasia. However, diagnostic excisional methods, including loop electrosurgical excision procedure and cold knife conization, are associated with an increased risk of adverse obstetric outcomes, such as preterm labor and low birth weight. Methods of endometrial assessment have a high sen- sitivity for detecting endometrial carcinoma and benign causes of uterine bleeding without unnecessary procedures. Endometrial biopsy can reliably detect carcinoma involving a large portion of the endometrium, but is suboptimal for diagnosing focal lesions. A 3- to 4-mm cutoff for endometrial thickness on transvaginal ultrasonography yields the highest sensitivity to exclude endometrial carcinoma in postmenopausal women. Saline infusion sonohysteros- copy can differentiate
    [Show full text]
  • Cervical Health Policies Program Description the Breast, Cervical and Colon Health Program (BCCHP) Screens Qualifying Clients for Cervical Cancer
    DOH 342-035 July 2018 Cervical Health Policies Program Description The Breast, Cervical and Colon Health Program (BCCHP) screens qualifying clients for cervical cancer. The program is funded through a grant from the Centers for Disease Control and Prevention (CDC). It is administered by the Washington State Department of Health which contracts with Prime Contractors throughout the state to implement the program regionally. The Prime Contractors subcontract with health care providers and organizations to provide direct services to individuals in their communities. BCCHP eligibility and screening policies reflect CDC guidelines. Eligibility & Coverage Gender Definitions for terms used in BCCHP policies • Cisgender - a person whose gender identification and birth sex are the same. • Transgender man - a person who identifies as male with a female-assigned birth sex. • Transgender woman - a person who identifies as female with a male-assigned birth sex. • Genderqueer - A person whose gender identity differs from the gender assigned at birth but may be less clearly defined than a transgender person. • Gender Non-binary - a person who neither identifies as a male nor female with either a female assigned birth sex or a male-assigned birth sex. • Agender – A person who does not identify with any gender. Eligible – Cisgender women and transgender men who meet the following criteria: Must meet all of the following: • Age 40-64 (through the end of the month of client’s 65th birthday). • Age 65+ if the client is not eligible for Medicare or ineligible for Medicare Part B at the time of enrollment. • Age 21-39 if the client is not covered by Family Planning or Title X Clinic funding • Uninsured or underinsured.
    [Show full text]
  • The Effects of Different Instruments and Suture Methods of Conization for Cervical Lesions
    www.nature.com/scientificreports OPEN The efects of diferent instruments and suture methods of conization for cervical lesions Xiaoyu Wang1, Lei Li 1*, Yalan Bi2, Huanwen Wu2, Ming Wu 1 & Jinghe Lang1 This study is to compare the surgical outcomes of patients undergoing cold knife conization (CKC) versus electrosurgical conization (ESC). Among 10,086 patients in a single center admitted between January 2000 and January 2019, CKS or ESC was used for grade 3 cervical intraepithelial neoplasia (CIN3) or more severe lesions. Modifed Sturmdorf or Figure-of-eight sutures were applied after conization. A regression model was used to determine the risk factors for margin involvement and short-term post-operative complications. In total, 7275 (72.1%) and 2811 (27.9%) patients underwent CKC and ESC, respectively. Women who underwent ESC were older and had a higher risk of margin involvement and endocervical glandular involvement than those who underwent CKC in univariate analysis. However, in the multivariate analysis, age (odds ratio [OR] 1.032, 95% confdence interval [95% CI] 1.025–1.038) and glandular involvement (OR 2.196, 95% CI 1.915–2.517) were the independent risk factors associated with margin involvement, but the incision methods used caused no signifcant diference. Modifed Sturmdorf sutures and Figure-of-eight sutures were applied in 3520 (34.9%) and 6566 (65.1%) patients, respectively. The modifed Sturmdorf sutures was the only risk factor associated with wound hemorrhage (OR 1.852, 95% CI 1.111–3.085) after adjusted with other epidemiological and surgical factors. Various incision or suture methods had similar risk of cervical stenosis.
    [Show full text]